FBR & Co Analysts Give Aurinia Pharmaceuticals Inc. (AUPH) a $9.00 Price Target
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has been assigned a $9.00 price objective by analysts at FBR & Co in a report issued on Wednesday. The firm currently has a a “buy” rating on the stock. FBR & Co’s price target indicates a potential upside of 116.35% from the company’s previous close.
A number of other equities research analysts also recently commented on AUPH. HC Wainwright started coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They issued a “buy” rating and a $7.00 target price on the stock. Leerink Swann restated an “outperform” rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. Finally, Canaccord Genuity set a $10.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 2.40% during midday trading on Wednesday, reaching $4.06. The company’s stock had a trading volume of 2,036,805 shares. The firm’s market capitalization is $143.26 million. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $5.69. The stock’s 50-day moving average price is $2.77 and its 200 day moving average price is $2.83.
Several large investors have recently bought and sold shares of the stock. Creative Planning purchased a new stake in Aurinia Pharmaceuticals during the third quarter valued at about $181,000. Lombard Odier Asset Management USA Corp boosted its position in Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares during the last quarter. Finally, Abingworth LLP boosted its position in Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock valued at $1,388,000 after buying an additional 423,729 shares during the last quarter. Hedge funds and other institutional investors own 20.04% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.